Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2004-03-1134PMID 15256429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

  2004cited by this paper
• Chronic myeloid leukemia-still a few questions.

  2004cited by this paper
• The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

  2003cited by this paper
• Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

  2003cited by this paper
• A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

  2003cited by this paper
• Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

  2003cited by this paper
• Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

  2003cited by this paper
• Molecular monitoring of chronic myeloid leukemia.

  2003cited by this paper
• Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

  2003cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

  2002cited by this paper
• Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571*

  2002influential reference
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  2002cited by this paper
• Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.

  2001cited by this paper
• The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.

  2001cited by this paper
• Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

  1999cited by this paper
• Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.

  1996cited by this paper
• Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.

  1995cited by this paper
• Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.

  1993cited by this paper
• Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation.

  1992cited by this paper
• Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction.

  1992cited by this paper
• Quantitative determination of the hybrid Bcr‐Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy

  1992cited by this paper

• Allele-Specific PCR for Detection of Missense Mutations in the Chimeric BCR::ABL1 Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients

  2025cites this paper
• miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape

  2025cites this paper
• Remission Depth in Metastatic Hormone-Sensitive Prostate Cancer Is Associated With Prognosis in Patients With Initial Prostate-Specific Antigen Values Above 100 Ng/ML

  2024cites this paper
• Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis

  2023cites this paper
• Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia

  2021cites this paper
• Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.

  2021cites this paper
• Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CTFR) in human bronchial epithelial cells

  2020cites this paper
• Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

  2020cites this paper
• Vardenafil increases intracellular accumulation of the most prevalent mutant CFTR in human bronchial epithelial cells.

  2020cites this paper
• ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.

  2020cites this paper
• Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Myeloid Leukemia, Version 2.2021

  2020cites this paper
• Therapeutic Challenges in Chronic Myeloid Leukemia: A Case-Based Discussion

  2020cites this paper
• Feasibility of Qualitative Testing of BCR‐ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT‐PCR Reversed Dot Blot Hybridization (RT‐PCR RDB)

  2019cites this paper
• New approaches of molecular monitoring in CML (and other diseases).

  2019cites this paper
• Translating insights into tumor evolution to clinical practice: promises and challenges

  2019cites this paper
• Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors

  2019cites this paper
• Comprehensive Monitoring of Patients with Chronic Myeloid Leukemia

  2018cites this paper
• Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia

  2018cites this paper
• Chronic Myeloid Leukemia , Version 1 . 2019 Clinical Practice Guidelines in Oncology

  2018cites this paper
• Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib

  2018cites this paper
• Chronic Myeloid Leukemia (CML)

  2018cites this paper
• Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

  2018cites this paper
• Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia

  2017cites this paper
• Tumor Profiling, Gene Expression Assays and Molecular Diagnostic Testing for Hematology/Oncology Indications

  2017cites this paper
• Smart applications of bionanosensors for BCR/ABL fusion gene detection in leukemia

  2017cites this paper
• A review of the challenge in measuring and standardizing BCR-ABL1

  2017cites this paper
• Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach

  2016cites this paper
• New Methodologies in the Molecular Monitoring of CML

  2016cites this paper
• Molecular monitoring of chronic myeloid leukemia: present and future

  2016cites this paper
• BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

  2016cites this paper
• [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)].

  2016cites this paper
• Monitoring disease burden in chronic myeloid leukemia: Past, present, and future

  2016cites this paper
• Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).

  2016cites this paper
• Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis

  2016cites this paper
• Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia.

  2015cites this paper
• Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance

  2015cites this paper
• Molecular monitoring in CML and the prospects for treatment-free remissions.

  2015cites this paper
• Phytohemagglutinin-Induced Peripheral Blood Cytogenetics: A Valid Means for Diagnosis and Imatinib Therapy Monitoring of Chronic Phase Chronic Myeloid Leukemia Patients

  2015influential citation
• Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India

  2014cites this paper
• Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.

  2014cites this paper
• Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

  2014cites this paper
• Monitoring Response to Treatment

  2014cites this paper
• Chapter-10 Chronic Myelogenous Leukemia

  2014cites this paper
• Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

  2014cites this paper
• Handbook of Chronic Myeloid Leukemia

  2014cites this paper
• Abl Kinase Domain Mutations in Imatinib-treated Egyptian Patients with Chronic Myeloid Leukemia

  2013cites this paper
• and imatinib sensitivity of transformed human hematopoietic cells Role of BCR/ABL gene-expression levels in determining the phenotype

  2013cites this paper
• domain mutation in patients with chronic myeloid leukemia on imatinib Determining the rise in BCR-ABL RNA that optimally predicts a kinase

  2013cites this paper
• Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era

  2013cites this paper
• BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.

  2013cites this paper
• Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR–ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction

  2013cites this paper
• Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

  2013cites this paper
• Chronic Myelogenous Leukemia, Version 1.2014.

  2013cites this paper
• the use and interpretation of monitoring methods modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on Monitoring the response and course of chronic myeloid leukemia in the

  2013cites this paper
• standard-dose imatinib therapy chronic myeloid leukemia in early chronic phase receiving high-dose or associated with increased risk of progression among patients with Delayed achievement of cytogenetic and molecular response is

  2013cites this paper
• BCR-ABL1 Kinase Domain Mutation Analysis in an Irish Cohort of Chronic Myeloid Leukemia Patients

  2013cites this paper
• Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib

  2013cites this paper
• Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines

  2013cites this paper
• Ultrasensitive detection of melamine based on a DNA-labeled immunosensor.

  2013cites this paper
• BCR–ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring

  2013cites this paper
• Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance

  2013cites this paper
• Imatinib

  2012cites this paper
• TKI resistance in CML cell lines : investigating resistance pathways.

  2012cites this paper
• Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

  2012cites this paper
• Tratamento da Leucemia Mielóide Crónica no Séc XXI

  2012cites this paper
• Chronic Myelogenous Leukemia

  2012cites this paper
• BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

  2012cites this paper
• Imatinib Resistance Mechanism on Chronic Myeloid Leukemia

  2012cites this paper
• Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey

  2012cites this paper
• 慢性髓细胞白血病对伊马替尼产生耐药性的机制 Imatinib Resistance Mechanism on Chronic Myeloid Leukemia

  2012cites this paper
• Molecular resistance: an early indicator for treatment change?

  2012cites this paper
• Practical monitoring of chronic myelogenous leukemia: when to change treatment.

  2012cites this paper
• Chronic Myeloid Leukemia

  2012cites this paper
• BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.

  2012cites this paper
• Optimizing second-line therapy for chronic myeloid leukemia.

  2012cites this paper
• BCR-ABL mutations in chronic myeloid leukemia.

  2011cites this paper
• Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

  2011influential citation
• Current treatment concepts of CML.

  2011cites this paper
• Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors

  2011cites this paper
• The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.

  2011cites this paper
• Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase

  2011cites this paper
• BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia

  2011cites this paper
• ORIGINAL ARTICLE Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

  2011cites this paper
• Detection of BCR-ABL kinase domain mutations in CD34 + cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance

  2011cites this paper
• Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

  2011cites this paper
• Molecular Diagnosis of Hematopoietic Neoplasms

  2011cites this paper
• Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia.

  2011cites this paper
• DEVELOPMENT OF ANALYTICAL METHODS IN METABOLOMICS FOR THE STUDY OF HEREDITARY AND ACQUIRED GENETIC DISEASE

  2011cites this paper
• Optimizing the Timing of Secondary TKIs The Philadelphia Chromosome and Bcr-Abl Breakpoints *

  2011cites this paper
• Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia

  2011cites this paper
• Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

  2011cites this paper
• Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

  2011cites this paper
• Monitoring response and resistance to treatment in chronic myeloid leukemia.

  2011cites this paper
• Molecular methods in diagnosis and monitoring of haematological malignancies

  2011influential citation
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cites this paper
• mutations and for expressing results transcripts and kinase domain BCR-ABL methodology for detecting inhibitors - Review and recommendations for 'harmonizing' current Monitoring CML patients responding to treatment with tyrosine kinase

  2011cites this paper